Crisis Interventions for Children and Adolescents with Depression and Suicidality: A Systematic Review and Meta-Analysis.

Curr Psychiatry RepOct 26, 2026 (epub)
Clinical ResearchPsychiatryPediatricsOpen access

Cristina Díaz-Téllez, Inmaculada Peñuelas-Calvo, Adrián Alacreu-Crespo et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined crisis services for children and adolescents experiencing acute mental health crises, including severe depression, suicidal ideation, self-harm, and suicidal behaviour. It included 15 studies evaluating 15 interventions. Four brief, structured interventions targeting suicidal ideation and self-harm reported reductions in suicidal thoughts, suicide attempts, and emergency department visits; family-focused approaches were associated with improved family functioning and fewer hospitalisations. Overall, crisis services may offer a promising alternative to hospitalisation, but the evidence is heterogeneous and largely observational, so causal conclusions cannot be drawn.

Key findings

  • Four interventions targeting suicidal ideation and self-harm reported reductions in suicidal thoughts, suicide attempts, and emergency department visits.
  • Seven family-focused interventions, evaluated in eight studies, improved communication and family cohesion and reduced hospitalisation rates.
  • Three crisis-stabilisation and community-linkage interventions improved continuity of care and decreased emergency service utilisation.
  • One residential intervention, evaluated in two studies, had mixed findings: some behavioural improvements but limited effects on internalising symptoms.

Why it matters

Acute crises in young people can involve substantial suicide risk and may lead to hospitalisation. The reviewed services offer intensive support in the young person’s natural environment and often involve family members. The findings suggest potential benefits across symptoms, service use, and family functioning, while underscoring that the current evidence is not strong enough to establish which models work best.

What to keep in mind

The evidence base is limited, largely observational, and heterogeneous; causal conclusions cannot be drawn. The review also identifies a need for direct comparisons between service models and long-term follow-up.

Source

Published in Curr Psychiatry Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.